How should an adult patient with cirrhosis and acute renal failure be managed, including treatment of possible hepatorenal syndrome?

Management of Cirrhosis with Acute Renal Failure

In adult patients with cirrhosis and acute renal failure, immediately withdraw diuretics, treat precipitating infections, and administer IV albumin 1 g/kg (max 100g/day) for 48 hours while rapidly determining if hepatorenal syndrome-AKI (HRS-AKI) is present within 24 hours to initiate vasoconstrictor therapy without delay. 1

Initial Assessment and Stabilization

First 24-48 Hours: Critical Diagnostic Window

The management paradigm has fundamentally shifted—HRS-AKI is no longer a diagnosis of exclusion and may coexist with other forms of AKI such as acute tubular necrosis 2. You must make the HRS-AKI determination within 24 hours, not after prolonged empiric trials.

Immediate actions:

• Stop all diuretics
• Identify and aggressively treat bacterial infections (most common precipitant of AKI in cirrhosis) 1
• Administer IV albumin 1 g/kg body weight (maximum 100g/day) for 48 hours 1
• Assess volume status carefully—avoid indiscriminate albumin administration as recent data show harm from volume overload and pulmonary edema in unselected patients 2

Diagnostic Criteria for HRS-AKI

HRS-AKI occurs only in patients with:

• Cirrhosis and ascites
• Often accompanied by systemic hypotension and hyponatremia
• Absence of these features makes HRS-AKI unlikely 1

Use biomarkers to differentiate:

• Neutrophil gelatinase-associated lipocalin (NGAL)
• Fractional excretion of sodium or urea
• These help distinguish acute tubular necrosis from functional causes 1

Pharmacologic Treatment Algorithm

For Stage 2 or Greater HRS-AKI (Serum Creatinine ≥2.5 mg/dL)

The treatment choice depends on clinical context:

Without Shock or ACLF-3:

Use terlipressin 0.5-2.0 mg IV every 6 hours (or continuous infusion 2 mg/24h) plus albumin 20-40g/day 1

• Start at 1 mg every 4-6 hours, increase up to 12 mg/day based on response
• Continue for up to 14 days
• Discontinue if no response by day 3-4
• Response rate: 36-44% reversal of HRS 1, 3
• Continuous infusion achieves same efficacy with lower total dose and fewer side effects 1

Critical monitoring for terlipressin:

• Watch for respiratory failure (occurs in 8-30% of patients, especially with ACLF-3) 1, 3
• Monitor for ischemic complications: angina, arrhythmia, digital/splanchnic ischemia 1, 3
• Do not resume if ischemic symptoms occur, even after resolution 3
• Monitor for pulmonary edema—patients may have cirrhotic cardiomyopathy or diastolic dysfunction 1
• Higher baseline MAP and oxygen saturation predict respiratory failure risk 3

Predictors of terlipressin response:

• Baseline bilirubin <10 mg/dL
• Baseline creatinine <5 mg/dL
• Lower ACLF stage
• Sustained MAP increase of 5-10 mmHg with treatment 3

Contraindications to terlipressin:

• ACLF-3 (EASL-CLIF criteria)
• Major cardiopulmonary disease
• Known ischemic vascular disease 1

With Shock:

Use norepinephrine as first-line agent 1

• Start 0.5 mg/h, increase by 0.5 mg/h every 4 hours
• Maximum 3 mg/h
• Goal: increase MAP by 10 mmHg or urine output >50 mL/h for ≥4 hours 3
• Response rate: 39-70% 3
• Requires ICU monitoring, adding significant cost 3
• In ACLF setting (bilirubin >5 mg/dL, INR >1.5 with hepatic encephalopathy or ascites within 4 weeks), terlipressin may be superior 3

Important Note on Stage 1 AKI:

There is currently no recommendation for vasoconstrictor use in Stage 1 AKI 1. The evidence base only supports treatment for Stage 2 or greater HRS-AKI.

Albumin Duration Controversy

The optimal duration of albumin administration with vasoconstrictors remains unclear 1. In recent trials, respiratory failure correlated with higher albumin volumes pre-treatment 1. Monitor carefully for volume overload and adjust based on clinical status rather than fixed protocols.

Avoid Midodrine/Octreotide

This combination should be largely abandoned due to lack of efficacy 2, despite historical use 3.

Renal Replacement Therapy (RRT)

Individualize RRT decisions, but generally recommend for:

• Patients who fail pharmacotherapy and
• Are listed or being considered for liver transplantation 1

RRT serves as a bridge to transplant, not definitive therapy.

Liver Transplantation: The Definitive Treatment

All patients with HRS-AKI who are potential transplant candidates should be referred for evaluation without delay 1. This is non-negotiable.

Simultaneous Liver-Kidney Transplant Criteria:

• Prolonged pre-transplant RRT >6 weeks
• Meet recently updated criteria 1

Benefits of Pre-Transplant Vasoconstrictor Therapy:

Even though vasoconstrictors may lower MELD score and delay transplant timing, post-transplant outcomes are significantly improved:

• Fewer patients need RRT post-transplant
• Less chronic kidney disease at 1 year post-transplant 1

Non-Transplant Candidates

Patients who are non-responders to pharmacotherapy and not transplant candidates should be referred for palliative care 1. The mortality without transplant remains extremely high.

Key Clinical Pitfalls to Avoid

1. Delayed diagnosis: The 48-hour albumin trial is no longer standard for all patients—determine HRS-AKI within 24 hours 2

2. Excessive albumin administration: Can cause fatal respiratory failure, especially with terlipressin and in patients with underlying cardiac dysfunction 1, 2

3. Missing infection: Infection is the most common precipitant (48% prevalence) and must be aggressively sought and treated 1

4. Using terlipressin in ACLF-3: Respiratory failure risk is prohibitive 1

5. Continuing terlipressin after ischemic events: Never resume even if symptoms resolve 3

6. Delayed transplant referral: Every day counts—refer immediately upon HRS-AKI diagnosis if potentially eligible 1

Prognostic Considerations

• Even small reductions in creatinine are beneficial: every 1 mg/dL drop reduces mortality risk by 27% 3
• Terlipressin may extend survival by 10 days without RRT—enough time to bridge to transplant 3
• Without transplant, prognosis remains poor despite medical therapy 4